SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpirax-Sarco Regulatory News (SPX)

Share Price Information for Spirax-Sarco (SPX)

Share Price is delayed by 15 minutes
Get Live Data
6,775.00    80.00 (1.19%)
Bid:
6,770.00
Ask:
6,780.00
Spread: 10.00 (0.148%)
Market Cap: £5.00b
SPX Live PriceLast checked at - London Stock Exchange

Intraday Spirax-Sarco Share Chart

Trading Update

14 Nov 2024 07:00

RNS Number : 1408M
Spirax Group PLC
14 November 2024
 

14 November 2024

Trading Update

Organic revenue growth ahead of first half; full year outlook unchanged

 

Spirax Group plc issues the following update in respect of the four months ended 31 October 2024.

Economic environment

Industrial Production Growth (IP) remained weak through the third quarter, with IP in our key geographic markets lower than was forecast by CHR at the time of our first half results in August. Following downward revisions to second half IP expectations in Europe and North America, CHR's full year forecast for global IP (excluding China) is now 0.9%, down from 1.5% in August. Macroeconomic conditions in China continue to remain challenging.

Trading

Against this weak macroeconomic backdrop, we have continued to focus on driving organic sales growth and preserving our adjusted operating profit margin.

Group organic sales growth for the ten months ended 31 October was ahead of the first half of the year with sales above the prior year comparator in all three Businesses, excluding currency effects. 

In the four months ended 31 October, Steam Thermal Solutions (STS) returned to organic sales growth. Sales in China, which accounted for close to 20% of STS sales in full year 2023, continued to be impacted by the weakness in large orders highlighted during the first half, although MRO sales continued to grow.

In Electric Thermal Solutions (ETS), organic sales growth was higher than in the first half. In the Industrial Process Heating segment, we increased shipments from our strong order book through delivery of ongoing operational improvements. In the Industrial Equipment Heating segment, organic sales growth was modestly positive against a weak prior year comparator as we have yet to see a recovery in demand from customers in the Semicon sector.

In Watson-Marlow, sales to Biopharm customers were supported by our order book that has continued to normalise towards lower historic levels. Process Industries organic sales growth improved further, above the first half of the year, supporting overall organic sales growth in Watson-Marlow. 

Financial position

Net borrowings (excluding leases) at 31 October were £642 million (30 June: £718 million), with the Group net debt to EBITDA ratio at 1.7x (30 June: 1.9x).

Outlook

Our full year outlook remains unchanged from that set out at our Capital Markets event on 3 October 2024. For the Group, we expect mid-single digit organic revenue growth for the full year and an adjusted operating profit margin broadly in line with the 2023 margin of approximately 20.0% (adjusted for currency headwinds). If exchange rates at the end of October were to prevail, the headwind impact across the full year would be approximately 1% greater on both sales and adjusted operating profit than we had expected at the time of our first half results in August.

Further information:

Louisa Burdett, Chief Financial Officer

+44 (0) 1242 240281

Mal Patel, Head of Investor Relations

+44 (0) 1242 240281

 

Media:

Martin Robinson, Teneo

+44 (0) 20 7260 2700

spiraxgroup@teneo.com

 

 

 

 

 

 

 

 

 

 

About Spirax Group plc

Spirax Group (formerly Spirax-Sarco Engineering) is positioned to play a critical role in enabling the industrial transition to net zero, aligned to our Purpose to create sustainable value for all our stakeholders as we engineer a more efficient, safer and sustainable world. We put solving customers' problems at the heart of our 'total solutions' approach. Our global thermal energy and fluid technology solutions improve operating efficiency and safety in our customers' critical industrial processes. Our new-to-world decarbonisation* solutions will use our proprietary technologies to electrify boilers, for the raising of steam, as well as the electrification of other critical industrial process heating applications.

Spirax Group comprises three strong and aligned Businesses: Steam Thermal Solutions helps customers control and manage steam within their mission critical industrial applications, such as cleaning, sterilising, cooking and heating. We are helping to put food safely on the world's tables and keeping our hospitals running. Electric Thermal Solutions has proprietary technologies that deliver electrification solutions at scale in industrial settings, including for the raising of steam, supporting our customers to achieve their net zero goals. We also deliver freeze protection and defrost solutions critical to aviation and space industries and ensure thermal uniformity in Semiconductor chip manufacturing to power the critical electronic systems we rely on.  Watson‐Marlow Fluid Technology Solutions is engineering vital fluid technology solutions that optimise the efficient use of resources and support advancements in global health, such as lifesaving vaccines and gene therapies.

Spirax Group is headquartered in Cheltenham (UK). We have 37 strategically located manufacturing plants around the world and are committed to creating a safe and inclusive working culture for our 10,000 colleagues, operating in 66 countries and serving 110,000 customers globally. 

The Company's shares have been listed on the London Stock Exchange since 1959 (symbol: SPX) and we are a constituent of the FTSE 100 and the FTSE4Good Indexes.

 

* Eliminates scope 1 and 2 greenhouse gas emissions when connected to a green electricity source.

 

Further information can be found at spiraxgroup.com

 

RNS filter: Trading Update

LEI 213800WFVZQMHOZP2W17 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBJBATMTIBBTI
Date   Source Headline
21st Nov 20173:08 pmRNSDirector/PDMR Shareholding
21st Nov 20177:00 amRNSTrading Statement
14th Nov 201710:39 amRNSDirector/PDMR Shareholding
16th Oct 20175:35 pmRNSDirector/PDMR Shareholding
29th Sep 20173:36 pmRNSHolding(s) in Company
9th Aug 20177:00 amRNSHalf-year Report
4th Jul 20177:00 amRNSCompletion of Acquisition
23rd Jun 20179:11 amRNSTotal Voting Rights
20th Jun 20173:59 pmRNSHolding(s) in Company
12th Jun 20172:20 pmRNSDirector/PDMR Shareholding
5th Jun 20179:08 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSAcquisition of Chromalox for US$415 million
9th May 20174:30 pmRNSResult of AGM
9th May 20177:00 amRNSTrading Statement
4th May 20174:30 pmRNSHolding(s) in Company
3rd May 20177:00 amRNSCompletion of Acquisition
26th Apr 20178:42 amRNSHolding(s) in Company
25th Apr 20179:10 amRNSHolding(s) in Company
19th Apr 20173:55 pmRNSHolding(s) in Company
18th Apr 20173:58 pmRNSHolding(s) in Company
3rd Apr 20177:30 amRNSAcquisition
24th Mar 20174:44 pmRNSTotal Voting Rights
23rd Mar 20171:45 pmRNSDirector/PDMR Shareholding
17th Mar 20174:04 pmRNSDirector/PDMR Shareholding
9th Mar 20177:00 amRNSFinal Results
30th Nov 20167:00 amRNSAcquisition
22nd Nov 20167:00 amRNSTrading Statement
17th Nov 20164:23 pmRNSDirector/PDMR Shareholding
14th Nov 20168:30 amRNSDr Krishnamurthy Rajagopal
10th Nov 201611:40 amRNSListing Application
8th Nov 201611:57 amRNSChange of Director Details
4th Nov 20164:27 pmRNSTotal Voting Rights
28th Oct 20167:00 amRNSBoard Succession Changes
17th Oct 20162:49 pmRNSAdditional Listing
14th Oct 20165:03 pmRNSDirector/PDMR Shareholding
14th Oct 20163:20 pmRNSTotal Voting Rights
14th Oct 20163:17 pmRNSBlock listing Interim Review
6th Oct 201611:48 amRNSNotification of Release Date - Trading Statement
8th Sep 201612:44 pmRNSTotal Voting Rights
18th Aug 20168:30 amRNSBoard Appointment
12th Aug 20163:51 pmRNSDirector/PDMR Shareholding
9th Aug 20167:05 amRNSSpirax Sarco acquires assets of Hiter for £3.9 m
9th Aug 20167:00 amRNS2016 Half Year Results
5th Aug 20162:56 pmRNSTotal Voting Rights
1st Jul 201611:43 amRNSTotal Voting Rights
29th Jun 20169:29 amRNSNotice of Results
21st Jun 20165:40 pmRNSDirector/PDMR Shareholding
10th Jun 20162:59 pmRNSHolding(s) in Company
2nd Jun 20164:20 pmRNSAdditional Listing
2nd Jun 20163:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.